CHEK2 and cancer: Genetic and pharmacological inhibition of CHEK2 in lymphoid and myeloid cell lines reduced PARPi-induced hematologic toxicity, further demonstrating that specific CHEK2 inhibition may be used to alleviate cancer treatment–induced toxicities (86).